ORGANIZATION
Public, Private Donors Put Up US$200-Plus Million for GHIT’s 2nd-Phase Work
Donors of the Global Health Innovative Technology Fund (GHIT Fund) has pledged a total of over US$200 million for its second-phase projects aimed at developing new tools to fight against the world’s neglected diseases - double the initial investment the…
To read the full story
Related Article
- GHIT Fund’s New 5-Year Strategic Plan Aims to Win Approval of 2 Products
December 12, 2017
ORGANIZATION
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





